Literature DB >> 2746668

MDR1 gene expression in lung cancer.

S L Lai1, L J Goldstein, M M Gottesman, I Pastan, C M Tsai, B E Johnson, J L Mulshine, D C Ihde, K Kayser, A F Gazdar.   

Abstract

The MDR1 gene (also known as PGY1) is frequently overexpressed in multidrug-resistant cell lines. We investigated the role of MDR1 gene expression in lung cancer by performing RNA slot blot analysis in samples from a panel of 24 lung cancers, 10 corresponding nontumorous lung tissues, and 67 tumor cell lines of several histologic types. Almost all of the tumors, nontumorous lung tissues, and cell lines expressed low levels of MDR1 RNA. Relatively higher levels were found in only one type of lung cancer, a subgroup of non-small cell lung cancers expressing neuroendocrine markers. No evidence of MDR1 gene amplification or rearrangements was detected. We found no correlation between MDR1 gene expression in cell lines and (a) in vitro chemosensitivity of the cells, (b) prior therapy status of the patients, or (c) clinical response to therapy. We conclude that the clinical multidrug resistance of many lung cancers cannot be explained solely on the basis of expression of the MDR1 gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2746668     DOI: 10.1093/jnci/81.15.1144

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  45 in total

1.  Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor.

Authors:  T W Gant; J A Silverman; S S Thorgeirsson
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

2.  The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.

Authors:  Michael M Gottesman; Ira H Pastan
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 3.  Role of RLIP76 in doxorubicin resistance in lung cancer.

Authors:  Rit Vatsyayan; Pankaj Chaudhary; Poorna Chandra Rao Lelsani; Preeti Singhal; Yogesh C Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

Review 4.  Genetic basis of multidrug resistance of tumor cells.

Authors:  S E Kane; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

5.  MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.

Authors:  E de Kant; I Heide; C Thiede; R Herrmann; C F Rochlitz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

Authors:  C D Evans; S E Mirski; M K Danks; S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.

Authors:  T W Beer; D C Rowlands; J Crocker
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

8.  MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.

Authors:  C Ramachandran; A Sauerteig; K S Sridhar; R J Thurer; A Krishan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Studies on low-level MDR cells.

Authors:  G Belvedere; E Dolfini
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.